U.S. Capital Wealth Advisors LLC Sells 595 Shares of Eli Lilly and Company $LLY

U.S. Capital Wealth Advisors LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% in the fourth quarter, HoldingsChannel reports. The firm owned 8,611 shares of the company’s stock after selling 595 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $9,254,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after buying an additional 551,659 shares during the period. State Street Corp increased its position in shares of Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after acquiring an additional 219,590 shares during the last quarter. Capital Research Global Investors increased its position in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP increased its position in Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after buying an additional 574,229 shares during the last quarter. Finally, Capital International Investors grew its position in shares of Eli Lilly and Company by 6.1% in the third quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock valued at $7,628,447,000 after purchasing an additional 579,381 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,224.59.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: ACHIEVE-4 Phase 3 results showed Foundayo was non‑inferior to insulin glargine and associated with lower major adverse cardiovascular events (MACE‑3 and MACE‑4), plus a large reduction in all‑cause death in a pre‑planned analysis — supportive for safety perceptions and long‑term adoption. ACHIEVE-4 press release
• Positive Sentiment: Wall‑street and media bullishness continues: new buy ratings and feature articles argue Lilly is taking the lead in the U.S. obesity market and that its obesity portfolio is driving outsized revenue growth — supportive for multiple expansion and investor confidence. TipRanks buy rating
• Positive Sentiment: Commercial rollout progress: telehealth/wellness platform Shed added Foundayo to its offerings, expanding patient access to an oral GLP‑1 alternative and potentially accelerating uptake vs. injectables. Shed adds Foundayo
• Positive Sentiment: Strategic R&D moves: Lilly agreed to acquire CrossBridge Bio (preclinical ADC specialist) for up to ~$300M to bolster its oncology pipeline and also expanded TuneLab partnerships (Vasa) — adds pipeline optionality beyond obesity. CrossBridge acquisition Vasa TuneLab partnership
• Neutral Sentiment: Media speculation on long‑term upside (e.g., $2,000 price narratives, market‑leadership think pieces) fuels optimism but is speculative and depends on sustained execution and pricing/payer dynamics. Forbes valuation piece
• Neutral Sentiment: Competitive landscape: Novo Nordisk’s moves (including an OpenAI deal) increase R&D/efficiency pressure in the weight‑loss arena — not an immediate hit to Lilly but relevant for longer‑term market share dynamics. Novo–OpenAI partnership
• Negative Sentiment: FDA has asked Lilly for additional post‑approval safety data on Foundayo, focusing on potential liver signals and cardiovascular events — this regulatory scrutiny raises uncertainty around labeling, prescribing behavior, payer coverage, and could slow uptake. FDA safety data request
• Negative Sentiment: Market reaction: headlines noting the stock slipped (intraday weakness) reflect investor caution as positive commercial and clinical news competes with the FDA request and elevated valuation metrics. Market reaction coverage

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $905.73 on Thursday. The stock has a market cap of $855.75 billion, a PE ratio of 39.47, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51. The firm has a fifty day moving average price of $976.09 and a 200-day moving average price of $979.89. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period last year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.